Ipca is a fully-integrated Indian pharmaceutical company manufacturing over 350 formulations and 80 APIs for various therapeutic segments. Contribution from Global Fund tenders, new anti-malaria products (injection and dispersible tabs), strong API pricing/demand, Bayshore acquisition and likely pick-up in UK revenues are the key drivers.
Further the company has reduced its debt dependency to 0.2x from 0.4x in FY14. Cash flow is also steadily increasing. Hence Buy.
View Full Report in Browser 
